Back to Top Skip to main content Skip to sub-navigation

Development of WRAIR’s Pan-Coronavirus Vaccine Shows Promise

Image of A vial of spike ferritin nanoparticle WRAIR's COVID-19 vaccine. A vial of spike ferritin nanoparticle (SpFN), WRAIR’s COVID-19 vaccine. Built on a ferritin platform, the vaccine offers a flexible approach to targeting multiple variants of the virus that causes COVID-19 and potentially other coronaviruses as well (Photo by: Mike Walters, Walter Reed Army Institute of Research).

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

A series of recently published preclinical study results show that the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed by researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland not only elicits a potent immune response but may also provide broad protection against SARS-CoV-2 variants of concern as well as other coronaviruses.

Scientists in WRAIR's Emerging Infectious Diseases Branch (EIDB) developed the SpFN nanoparticle vaccine, based on a ferritin platform, as part of a forward-thinking "pan-SARS" strategy that aims to address the current pandemic and acts as a first line of defense against variants of concern and similar viruses that could emerge in the future.

"The accelerating emergence of human coronaviruses throughout the past two decades and the rise of SARS-CoV-2 variants, including most recently Omicron, underscore the continued need for next-generation preemptive vaccines that confer broad protection against coronavirus diseases," said Dr. Kayvon Modjarrad, director of the Emerging Infectious Diseases Branch at WRAIR, co-inventor of the vaccine and the Army lead for SpFN. "Our strategy has been to develop a 'pan-coronavirus' vaccine technology that could potentially offer safe, effective and durable protection against multiple coronavirus strains and species."

Pre-clinical studies published today in Science Translational Medicine indicate that the SpFN vaccine protects non-human primates from disease caused by the original strain of SARS-CoV-2 and induces highly-potent and broadly-neutralizing antibody responses against major SARS-CoV-2 variants of concern including the SARS-CoV-1 virus that emerged in 2002.

SpFN entered Phase 1 human trials in April 2021. Early analyses, expected to conclude this month, will provide insights into whether SpFN's potency and breadth, as demonstrated in preclinical trials, will carry over into humans. The data will also allow researchers to compare SpFN's immune profile to that of other COVID-19 vaccines already authorized for emergency use.

"This vaccine stands out in the COVID-19 vaccine landscape," Modjarrad said. "The repetitive and ordered display of the coronavirus spike protein on a multi-faced nanoparticle may stimulate immunity in such a way as to translate into significantly broader protection."

WRAIR developed a secondary candidate vaccine, a SARS-CoV-2 Spike Receptor-Binding Domain Ferritin Nanoparticle (RFN) vaccine, which targets a smaller part of the coronavirus Spike protein than the SpFN vaccine. Results from a study, published recently in the Proceedings of the National Academy of Sciences, show that this vaccine potentially offers similar protection against an array of SARS-CoV-2 variants and SARS-CoV-1.

"The RFN vaccine candidate is more compact and has some natural advantages as we try to increase the immune response against multiple coronaviruses using a single vaccine platform, so it is still under consideration as part of our pan-coronavirus vaccine development pipeline," said Dr. Gordon Joyce, WRAIR structural biologist and vaccine co-inventor.

"The threat from COVID-19 continues as it evolves, and eventually there will be other emerging disease threats," said Dr. Nelson Michael, director of the Center for Infectious Diseases Research at WRAIR. "Our investment in developing a next generation vaccine is an important step towards getting ahead of COVID-19 and future disease threats."

You also may be interested in...

COVID-19: Bivalent Boosters

Infographic
9/19/2022
COVID-19: Bivalent Boosters

COVID-19 Bivalent Booster are now available!

Recommended Content:

Coronavirus and the COVID-19 Vaccine

COVID-19: Bottom Line on Boosters

Infographic
9/19/2022
COVID-19: Bottom Line on Boosters

Bottom Line on Boosters: Stay up to date!

Recommended Content:

Coronavirus and the COVID-19 Vaccine

COVID-19: Bivalent Booster, Did you know?

Infographic
9/19/2022
COVID-19: Bivalent Booster, Did you know?

Updated COVID-19 Boosters available!

Recommended Content:

Coronavirus and the COVID-19 Vaccine

COVID-19: Bivalent Booster, New

Infographic
9/19/2022
COVID-19: Bivalent Booster, New

New Booster for Fall!

Recommended Content:

Coronavirus and the COVID-19 Vaccine

COVID-19: Bivalent Booster, Get Boosted

Infographic
9/19/2022
COVID-19: Bivalent Booster, Get Boosted

Get Boosted!

Recommended Content:

Coronavirus and the COVID-19 Vaccine

DHA Form 207: COVID-19 Vaccine Screening and Immunization Document v22

Form/Template
9/9/2022

The purpose of this form is to determine if the COVID-19 vaccine can be administered to the patient. (v22, Sept. 2022)

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Immunization Healthcare Division | COVID-19 Vaccine Efforts | COVID-19 Information for Military Treatment Facility Directors | Coronavirus

Ramstein Now Offers Novavax Vaccine

Article Around MHS
9/8/2022
Military medical gives Soldier a COVID-19 vaccine

The 86th Medical Group is now offering the Novavax COVID-19 vaccine, which has been authorized for emergency use by the U.S. Food and Drug Administration, to members 18 years and older in the Kaiserslautern Military Community.

Recommended Content:

Immunization Healthcare Division | COVID-19 Vaccine Efforts | Immunizations | Coronavirus

Novavax COVID-19 Vaccine Now Available for 12 to 17 Year-Olds

Article
8/30/2022
Air Force Staff. Sgt. fills a syringe with a COVID-19 vaccine at Ramstein Air Base, Germany.

Novavax COVID-19 Vaccine is Available for Those 12 Years' Old and Above

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vaccine Efforts

New COVID-19 Boosters Against Subvariants Coming Soon

Article
8/29/2022
Marine on right gets a COVID-19 booster vaccination from a nursing student on his left.

Brooklyn Marine gets COVID-19 booster vaccination.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vaccine Efforts

How to Get Your Kids Up to Date on Vaccinations

Article
8/25/2022
Child wearing a mask getting the COVID-19 vaccine

Resources to help you get and keep your child’s immunizations up to date in time for back to school.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Back to School Immunizations | Immunization Healthcare Division

COVID-19 Vaccines

Infographic
8/18/2022
COVID-19 Vaccines

How COVID-19 Vaccines Work – There are three types of vaccines currently available: mRNA, subunit protein, and viral vector. Pfizer and Moderna are mRNA vaccine. Novavax is a subunit protein vaccine. Janssen is a viral vector vaccine. All products resemble a virus for the immune system to fight.

Recommended Content:

Coronavirus and the COVID-19 Vaccine

COVID-19 Novavax Vaccine

Infographic
8/18/2022
COVID-19 Novavax Vaccine

The Novavax COVID-19 Vaccine, Adjuvanated includes two doses, 21 days apart. Remember to mark your calendar and schedule time for your second dose.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Types of COVID-19 Vaccines

Consolidated Department of Defense Coronavirus Disease 2019 Force Health Protection Guidance

Policy

Consolidates and updates the Department’s guidance regarding vaccination verification, vaccination status, COVID-19 testing, surveillance and screening testing, personnel protection on-site mask requirements, (e.g., DHA military medical treatment facilities, meetings, travel), and the protection of personally identifiable information.

COVID-19 Moderna Vaccine

Publication
8/17/2022

Moderna and mRNA vaccines are available. Moderna includes two doses, 28 days apart.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Get to Know the COVID-19 Vaccines | Types of COVID-19 Vaccines | Coronavirus & the MHS Response

COVID-19 Pfizer Vaccine

Publication
8/17/2022

Pfizer mRNA vaccines are available. Pfizer includes two doses, 21 days apart.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Get to Know the COVID-19 Vaccines | Types of COVID-19 Vaccines | Coronavirus & the MHS Response
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 34
Refine your search
Last Updated: December 28, 2021

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.